



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
1401 Rockville Pike
Rockville MD 20852-1448

Our Reference Nos.: 97-1148 and 97-1157

March 25, 1999

Mary E. Martinson
Assistant Director, Biologics Submissions
U.S. Regulatory Affairs
Glaxo Wellcome Inc.
Five Moore Drive
Research Triangle Park, NC 27709

Dear Ms. Martinson:

Enclosed is Department of Health and Human Services U.S. License No. 0129 issued in accordance with the provisions of Section 351 (a) of the Public Health Service Act, as amended November 21, 1997 (FDAMA; Public Law 105-115), controlling the manufacture and sale of biological products. This license authorizes Wellcome Foundation Limited Wellcome Research Laboratories, Beckenham, Kent, United Kingdom to introduce or deliver for introduction into interstate commerce, those products for which your company has demonstrated compliance with establishment and product standards.

Under this license you are hereby authorized to manufacture and ship the product Interferon alfa-n1, Lymphoblastoid. Interferon alfa-n1, Lymphoblastoid is indicated for the treatment of chronic hepatitis C in patients 18 years of age or older without decompensated liver disease.

Under this authorization, you are approved to manufacture Interferon alfa-n1, Lymphoblastoid at your facility in West Greenwich, Rhode Island. Purification and production of the final bulk will be performed at your facility in Beckenham, Kent, United Kingdom and drug product will be filled and labeled and packaged at your facility in Dartford, Kent, United Kingdom. Interferon alfa-n1, Lymphoblastoid will be distributed by your facility in Durham, North Carolina. In accordance with approved labeling, your product will bear the tradename WELLFERON, and will be marketed in a 1 mL fill size.

The dating period for this product shall be 24 months from the date of manufacture when stored at 5°C. The date of manufacture shall be defined as the date of final sterile filtration of the formulated product. The dating period for the purified bulk blend shall be 4 weeks when stored at 5°C. The dating period for the stabilized bulk blend shall be 6 months when stored at 5°C. The dating period for the formulated final bulk shall be 7 days when stored at 5°C. Results of ongoing stability studies should be submitted throughout the dating period as they become available including

the results of stability studies from the first three production lots. The stability protocol in your license application is considered approved for the purpose of extending the expiration dating period of your drug substance(s) and drug product as specified in 21 CFR 601.12.

You are required to submit to the Center for Biologics Evaluation and Research (CBER) samples of final container product for each future lot and the corresponding protocols showing results of all applicable tests. No lots of product shall be distributed until notification of release is received from the Director, CBER.

Any changes in the manufacture, packaging or labeling of the product or in the manufacturing facilities will require the submission of information to your biologics license application for our review and written approval consistent with 21 CFR 601.12.

It is requested that adverse experience reports be submitted in accordance with the adverse experience reporting requirements for licensed biological products (21 CFR 600.80) and that distribution reports be submitted as described (21 CFR 600.81). All adverse experience reports should be prominently identified according to 21 CFR 600.80 and be submitted to the Center for Biologics Evaluation and Research, HFM-210, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448.

Please submit three copies of all final printed labeling at the time of use and include part II of the label transmittal form (FDA Form 2567) with completed implementation information. In addition, you may wish to submit draft copies of the proposed introductory advertising and promotional labeling with an FDA Form 2567 or Form 2253 to the Center for Biologics Evaluation and Research, Advertising and Promotional Labeling Staff, HFM-202, 1401 Rockville Pike, Rockville, MD 20852-1448. Final printed advertising and promotional labeling should be submitted at the time of initial dissemination, accompanied by an FDA Form 2567 or Form 2253.


All promotional claims must be consistent with and not contrary to approved labeling. No comparative promotional claim or claim of superiority over other similar products should be made unless data to support such claims are submitted to and approved by the Center for Biologics Evaluation and Research.

The supplement to your Establishment License Application to include areas for the manufacture of Interferon alfa-n1, Lymphoblastoid in your facilities in West Greenwich, Rhode Island, Beckenham, Kent, United Kingdom, and Dartford, Kent, United Kingdom has been approved.


Page 3 - Ms. Martinson

Please acknowledge receipt of the enclosed Biologics License to the Director, Division of Application Review and Policy, Office of Therapeutics Research and Review, HFM-585.

Sincerely yours,



Steven A. Masiello
Acting Director
Office of Compliance
and Biologics Quality
Center for Biologics
Evaluation and Research



Jay P. Siegel, M.D., FACP
Director
Office of Therapeutics
Research and Review
Center for Biologics
Evaluation and Research

Enclosure